Aurobindo Pharma’s wholly owned subsidiary -- Helix Healthcare B.V, has entered into a binding agreement on December 22, 2025 with Shandong Luoxin Pharmaceutical Group Stock Co., China (Shandong Luoxin), the joint venture partner in Luoxin Aurovitas Pharma (Chengdu) Co., China (Luoxin Aurovitas), a 30:70 joint venture company between Helix and Shandong Luoxin, to acquire 20% additional ownership in Luoxin Aurovitas.
The object of acquisition is to expand the manufacturing to economies of scale by adding 2 high Speed Lines and cater market demand. Cost of acquisition is $5.12 million.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
